Impact of Turmeric as Dietary approach on HER2 expression in blood of Gastric cancer Patients
Keywords:
Subjects, Curcumin, HER2, HPLC, Blood, BioavailabilityAbstract
Curcumin as an active ingredient of turmeric acts as repressor against proteins expressed in cancerous cell. However, due to poor absorption, little is known about the effect of curcumin on HER2 expression in blood. A blood samples were drawn from ten subjects of gastric cancer aged 37 to 80 years using turmeric as random doses in diet. For hypothesising of study, subjects were convinced to use a constant dose (500 mg) of turmeric twice in a day till the five days and then blood was drawn. Out of ten, three subjects had detectable curcumin, whereas in blood of nine subjects including three showed overexpression of HER2 status (>15 ng/ml) at random doses of turmeric. At constant dose (500 mg) of turmeric, six subjects out of ten had increasing curcumin level with decreasing HER2 status in blood, whereas in two subjects, HER2 status was remain unchanged due to no detection of curcumin. In other two subject underwent for chemotherapy had low HER2 status without curcumin detection. An inverse relation of curcumin holds on HER2 status in blood of four subjects with different body mass of same age group after taking constant doses of turmeric powder. The curcumin bioavailability in blood depending on higher doses of turmeric and physical status of subjects may inhibit the HER2 expression.
References
Shishodia S, Sethi G, and Aggarwal BB. Curcumin: getting back to the roots. Annals of the New York Academy of Sciences 2005; 1056: 206.
Jemal A, Murray T, Ward E et al. Cancer statistics. CA Canc. J. Clin. 2005; 55: 10-30.
Sharma RA, Gescher AJ, and Steward WP. Curcumin: the story so far. Eur J Canc. 2005; 41: 1955.
Singh S, and Khar A. Biological effect of curcumin and its role in cancer chemoprevention and therapy. Anti-cancer Agents in Med Chem. 2006; 6: 415.
Ammon HPT, and Wahl MA. Pharmacology of curcuma longa. Planta Med. 1991; 57: 1-7.
Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 2006; 66: 613-621.
Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-I down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106: 2503-2513.
Coussens L, Yang-Feng TL, Lioa YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95: 142-153.
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-postive early breast cancer. N Engl J Med. 1994; 330: 1260-1266.
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-2251.
Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price C. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49: 1579-1598.
Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Gimenez N, Hage M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996; 16: 2295-300.
Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemopreventive by curcumin. AAPS J. 2006 ; 8: 443-9.
Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006; 78: 2081-7.
Bokoch GM. Biology of the p-21 activated kinases. Annu Rev Biochem. 2003; 72: 743-81.
Lin JK. Molecular targets of curcumin. Adv Exp Med Biol. 2007; 595: 227-43.
Cai, Xin-Ze, Wang Jian, Li Xiao-Dong, Wang Gui-Ling, Liu Fu-Nan, Cheng Mao-sheng, and Li Feng. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biology & Therapy 2009; 8: 1360-1368.
Yang KY, Lin LC, Tseng TY, Wang SC, Tsai THJ. Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853: 183-189.
Tonnesen HH, Masson MLT. Int J Pharm. 2002; 244: 127-135.
Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ. Canc Epidemiol Biomarkers Prev. 2002; 11: 535-540.
Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Canc Res. 2004; 10: 6847-54.
Araujo CC, Leon LL. Biological activities of curcuma longa L. Memorias do Instituto Oswaldo Cruz. 2001; 96: 723-728.
Pan MH, Huang TM, and Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999; 27: 486-494.
Holder GM, Plummer JL, and Ryan AJ. The metabolism and excretion of curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6, heptadiene-3,5-dione] in the rat. Xenobio. 1978; 8: 761-768.
Heath DD, Pruitt MA, Brenner DE, Rock CL. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003; 783: 287-95.
ASTA. Official Analytical Methods; American spice Trade Association. Englewood cliff NJ, Method (18)color power of turmeric 1958.
Anand P, Kunnumakkara AB, Newman RA, Aggarmwal BB. Mol. Pharm. 2007; 4: 807-818.
Vijayalakshmi R, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicol. 1980; 16: 259-65.
Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL, and Robertson JFR. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Canc. Res. 2007; 9: R75.
Vareed KS, Madhuri K, Mack T, Ruffin et al. Pharmacokinetics of Curcumin Conjugates Metabolites in Healthy Human Subjects. Canc Epidemiol Biomarkers Prev. 2008; 17: 1411-1417.
Bisht, Savita, Maitra, Anirban. Systemic delivery of curcumin: 21st century solutions for an ancient Conundrum. Current Drug Discovery Technol. 2009; 6: 192-199.
